Company intelligence / Profile preview

Joshua M Hare

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Longeveron is a clinical-stage biotechnology company focused on developing regenerative medicines for life-threatening and chronic aging-related conditions. The company's core technology is Lomecel-B, an allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy designed to promote tissue repair and reduce inflammation. Longeveron is currently advancing clinical programs in Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease, and Aging Frailty. Founded by Dr. Joshua M. Hare, a pioneer in stem cell research, the company is headquartered in Miami and is publicly traded on the NASDAQ. The company leverages its proprietary manufacturing process to produce high-quality cell therapies for its diverse clinical pipeline.

Therapeutic areas: CardiovascularNeurologyOther
Modalities: Cell therapyStem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Joshua M Hare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Joshua M Hare.